POLYCLONARL ANTIBODY DIRECTED AGAINST HOMOCYSTEINE THIOLACTONE MODIFIEDLDL
针对高半胱氨酸硫内酯修饰LDL的多克隆抗体
基本信息
- 批准号:6279881
- 负责人:
- 金额:$ 0.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1998
- 资助国家:美国
- 起止时间:1998-04-01 至 1999-02-28
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Homocysteinemia is presumed to be responsible for the development
of atherosclerosis, however, the precise etiology is unclear. We
examined the possibility that the homocystamide-LDL adduct, a product
of the reaction between homocysteine thiolactone and apo-B lysyl
residues, was immunogenic. New Zealand white rabbits were immunized
with this adduct at 6-week intervals. Antibody titers (ca. 100,000)
were determined in antisera collected following the third immunization
using solid-phase ELISA techniques. In competition-based ELISAs,
homocysteine thiolactone-treated LDL competed for binding with the
antiserum, as the 50% inhibitory concentration was approximately 10
micrograms/ml. Neither homocysteine, homocystine, nor Cu(2+)-oxidized
LDL competed for binding. LDL in which lysyl residues were
derivatized by acetylation or methylation were not recognized by the
antiserum. All lipoprotein fractions from homocysteine
thiolactone-treated plasma competed for binding to the antiserum. We
conclude that homocysteine thiolactone-modified LDL is highly
immunogenic and specific for homocystamide-lysyl adducts. This
antibody has the potential to be used as a diagnostic tool for
measuring plasma homocysteine and for delineating the role of
homocysteinemia in vascular disease.
同型半胱氨酸血症被认为是导致
然而,动脉粥样硬化的确切病因尚不清楚。 我们
研究了同型半胱氨酸-低密度脂蛋白加合物的可能性,
同型半胱氨酸硫内酯与载脂蛋白B赖氨酰之间的反应
残基,具有免疫原性。 免疫新西兰白色兔
每隔6周注射一次 抗体滴度(ca. 10万人)
在第三次免疫后收集的抗血清中测定
使用固相ELISA技术。 在基于竞争的ELISA中,
同型半胱氨酸硫代内酯处理的LDL竞争与
抗血清,因为50%抑制浓度约为10
微克/毫升。 同型半胱氨酸、同型胱氨酸和Cu(2+)均未氧化
LDL竞争结合。 其中赖氨酰残基
通过乙酰化或甲基化衍生的,不被识别,
抗血清 来自同型半胱氨酸的所有脂蛋白组分
硫内酯处理的血浆竞争结合抗血清。 我们
结论是同型半胱氨酸硫代内酯修饰的LDL是高度
免疫原性且对高胱氨酸-赖氨酰加合物具有特异性。 这
抗体有可能被用作诊断工具,
测量血浆同型半胱氨酸和描绘的作用,
血管疾病中同型半胱氨酸血症
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ERIC FERGUSON其他文献
ERIC FERGUSON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ERIC FERGUSON', 18)}}的其他基金
MECHANISM OF APOLIPOPROTEIN B 100 THIOL DEPLETION DURING OXIDATION OF LDL
LDL 氧化过程中载脂蛋白 B 100 硫醇消耗的机制
- 批准号:
6307907 - 财政年份:2000
- 资助金额:
$ 0.5万 - 项目类别:
POLYCLONARL ANTIBODY DIRECTED AGAINST HOMOCYSTEINE THIOLACTONE MODIFIEDLDL
针对高半胱氨酸硫内酯修饰LDL的多克隆抗体
- 批准号:
6307906 - 财政年份:2000
- 资助金额:
$ 0.5万 - 项目类别:
ANTIOXIDANT POTENTIAL OF HOMOCYSTAMIDE LDL ADDUCT
同型半酰胺低密度脂蛋白加合物的抗氧化潜力
- 批准号:
6307877 - 财政年份:2000
- 资助金额:
$ 0.5万 - 项目类别:
POLYCLONAL ANTIBODY DIRECTED AGAINST HOMOCYSTEINE THIOLACTONE MODIFIED LDL
针对同型半胱氨酸硫内酯修饰的 LDL 的多克隆抗体
- 批准号:
6118862 - 财政年份:1999
- 资助金额:
$ 0.5万 - 项目类别:
MECHANISM OF APOLIPOPROTEIN B 100 THIOL DEPLETION DURING OXIDATION OF LDL
LDL 氧化过程中载脂蛋白 B 100 硫醇消耗的机制
- 批准号:
6279882 - 财政年份:1998
- 资助金额:
$ 0.5万 - 项目类别:
ANTIOXIDANT POTENTIAL OF HOMOCYSTAMIDE LDL ADDUCT
同型半酰胺低密度脂蛋白加合物的抗氧化潜力
- 批准号:
6279846 - 财政年份:1998
- 资助金额:
$ 0.5万 - 项目类别:
RADICAL MEDIATED APOLIPOPROTEIN B 100 THIOL DEPLETION
自由基介导的载脂蛋白 B 100 硫醇消耗
- 批准号:
6250044 - 财政年份:1997
- 资助金额:
$ 0.5万 - 项目类别:
HOMOCYSTEINE IN MODIFICATION OF LOW DENSITY LIPOPROTEIN
同型半胱氨酸修饰低密度脂蛋白
- 批准号:
6250043 - 财政年份:1997
- 资助金额:
$ 0.5万 - 项目类别:
APOLIPOPROTEIN B 100 THIOL DEPLETION DURING OXIDATION OF LDL
LDL 氧化过程中载脂蛋白 B 100 硫醇消耗
- 批准号:
5222143 - 财政年份:
- 资助金额:
$ 0.5万 - 项目类别: